Medically supervised Wegovy (semaglutide 2.4mg) treatment online — available to patients across New Jersey and all 50 states. No long waits. No in-person visits required.
Book a Free Zoom ConsultationWegovy is the brand name for semaglutide 2.4mg, a once-weekly injectable medication approved by the FDA specifically for chronic weight management in adults with obesity or overweight conditions accompanied by at least one weight-related health concern, such as high blood pressure, high cholesterol, or type 2 diabetes.
Unlike older weight loss medications, Wegovy works at the hormonal level — targeting the same biological pathways that regulate appetite, metabolism, and blood sugar. It was developed by Novo Nordisk and approved by the FDA in June 2021 after extensive clinical trials demonstrating exceptional effectiveness for meaningful, sustained weight loss.
At NJ Weight Loss & Preventive Care Clinics PA, our Clinical Director personally oversees Wegovy protocols to ensure every patient receives individualized, medically sound care — whether they're located in New Jersey or anywhere else in the country.
Wegovy belongs to a class of medications called GLP-1 receptor agonists. GLP-1 (glucagon-like peptide-1) is a naturally occurring hormone your body releases after eating. It signals your brain that you're full, slows gastric emptying so food stays in your stomach longer, and helps regulate blood sugar levels.
In people who struggle with obesity, this signaling system is often dysregulated — the body doesn't produce enough GLP-1 at the right times, or the brain doesn't respond to it adequately. Semaglutide, the active ingredient in Wegovy, mimics this hormone with a much longer duration of action than the natural version. A single weekly injection keeps GLP-1 receptor activity elevated throughout the week.
The practical result: most patients experience a significant and sustained reduction in appetite, fewer food cravings, a natural tendency to eat smaller portions, and steadier blood sugar levels throughout the day. These effects combine to create a caloric deficit that produces real, measurable weight loss — without requiring extreme willpower or unsustainable restriction.
It is important to understand that Wegovy is most effective as part of a comprehensive approach that includes lifestyle guidance. Our clinical team provides ongoing support, check-ins, and adjustments throughout your treatment.
Wegovy has one of the most robust evidence bases of any weight-loss medication ever approved. The STEP clinical trial program — a series of large, randomized, placebo-controlled studies — enrolled thousands of adults and produced results that changed how the medical community approaches obesity treatment.
Adults on Wegovy lost an average of 14.9% of body weight over 68 weeks — compared to 2.4% in the placebo group. Over one-third of participants lost more than 20% of their body weight.
In adults with type 2 diabetes, Wegovy still produced an average of 9.6% weight loss — far exceeding most other treatment options available to this population.
When Wegovy was combined with intensive behavioral counseling and a low-calorie diet, participants lost an average of 16% of body weight — demonstrating that lifestyle support amplifies results.
The SELECT trial showed that semaglutide 2.4mg reduced the risk of major cardiovascular events by 20% in adults with obesity and established cardiovascular disease — a landmark finding that extended Wegovy's FDA indication.
The FDA has approved Wegovy for adults who meet specific clinical criteria. During your consultation, our clinical team will review your health history to confirm candidacy and identify any contraindications.
Adults classified as obese (BMI ≥ 30) are FDA-indicated candidates for Wegovy as a chronic weight management medication.
Adults with a BMI of 27 or above who have at least one weight-related condition — such as hypertension, high cholesterol, sleep apnea, or type 2 diabetes — also qualify.
Wegovy works best for patients committed to combining medication with healthier eating patterns and increased physical activity. It is not a short-term fix.
Patients with a personal or family history of medullary thyroid carcinoma, MEN2 syndrome, or a prior serious reaction to semaglutide are not candidates. We screen thoroughly during intake.
Our entire process is designed around your convenience. You never need to come into a physical office — though we do maintain two New Jersey clinic locations for patients who prefer in-person visits.
Schedule a video call with our clinical team. This is a real clinical conversation — not a sales call. We'll review your health history, goals, and whether Wegovy is appropriate for you.
Fill out our secure medical intake forms online. We collect your health history, current medications, lab work (if available), and any relevant prior medical records.
Our licensed provider reviews your intake and, if appropriate, issues a prescription. We work with established, licensed pharmacies to fill Wegovy and handle the logistics of getting it to you.
Wegovy is shipped directly to your home or a preferred location. We provide clear injection instructions and resources so you feel confident from day one.
Wegovy is started at a low dose and gradually increased over 16–20 weeks to reach the 2.4mg maintenance dose. We monitor your progress, manage side effects, and adjust your protocol as needed throughout treatment.
Yes. NJ Weight Loss & Preventive Care Clinics PA offers Wegovy online. You can complete your consultation, intake, and follow-up visits entirely online. We are licensed to serve patients in New Jersey and all 50 states.
Both Wegovy and Ozempic contain semaglutide, but they are FDA-approved for different purposes and at different doses. Ozempic (up to 1mg or 2mg) is approved for type 2 diabetes management. Wegovy (2.4mg) is specifically approved for chronic weight management. Using the correct medication for the correct indication matters — both clinically and for insurance coverage purposes.
The most frequently reported side effects are gastrointestinal in nature — nausea, constipation, diarrhea, vomiting, and stomach discomfort. These effects are most common during dose increases and typically improve over time. The gradual titration schedule used with Wegovy is specifically designed to minimize these side effects. Serious adverse events are rare but do exist, and our clinical team discusses them with every patient before starting treatment.
Many patients begin to notice reduced appetite and some initial weight loss within the first 4–8 weeks, even at the starting dose. Significant weight loss typically becomes apparent after reaching higher dose levels at weeks 8–16. Peak results are generally seen after 52–68 weeks of consistent use. Wegovy is intended as a long-term medication, not a short course.
Wegovy has experienced supply challenges in the past. Our clinical team monitors availability and can discuss alternative semaglutide formulations or transition strategies when appropriate. We will always work with you to maintain continuity of care and protect your progress.
No in-person visit is required. Our online platform serves patients wherever they are. That said, we do maintain physical clinic locations at 420 Route 46 East in Fairfield, NJ and 1605 E Evesham Road in Voorhees, NJ for patients who prefer face-to-face care.
Sign up for our email or SMS list to receive educational content, program updates, and exclusive information about our weight management services. No spam — ever.